Table 5.
Serum concentrations of various markers in patients with HCC (n = 147).
| Variables | N-HCC a vs. A-HCC b | N-HCC a vs. Healthy Subject | A-HCC b vs. Healthy Subject | |||
|---|---|---|---|---|---|---|
| Mean ± SEM | P-Value h | Mean ± SEM | P-Value h | Mean ± SEM | P-Value h | |
| GPC3 c (ng/mL) | 5.1± 1.2 vs. 3.4 ± 0.9 |
0.265 | 5.1± 1.2 vs. < 0.01 |
<0.001 | 3.4± 0.9 vs. < 0.01 |
0.001 |
| SPP1 d (ng/mL) | 52.2 ± 8.3 vs. 58.2 ± 6.5 |
0.570 | 52.2 ± 8.3 vs. 13.0 ± 1.6 |
<0.001 | 58.2 ± 6.5 vs. 13.0 ± 1.6 |
<0.001 |
| IGF-1 e (ng/mL) | 104 ± 11 vs. 92 ± 8 |
0.380 | 104 ± 11 vs. 195 ± 18 |
0.001 | 91.7± 7.8 vs. 195 ± 18 |
<0.001 |
| HGF f (pg/mL) | 952 ± 123 vs. 1043 ± 120 |
0.596 | 952 ± 123 vs. 909 ± 38 |
0.741 | 1043 ± 120 vs. 909 ± 38 |
0.292 |
| VEGF g (pg/mL) | 137 ± 12 vs. 145 ± 13 |
0.623 | 137 ± 12 vs. 179 ± 16 |
0.164 | 145 ± 12 vs. 179 ± 16 |
0.300 |
a Normal α-fetoprotein hepatocellular carcinoma b Abnormal α-fetoprotein hepatocellular carcinoma c Glypican-3 d secreted phosphoprotein 1 (SPP1), also known as osteopontin (OPN) e Insulin-like growth factor 1 f Hepatocyte growth factor g Vascular endothelial growth factor h Student’s t test.